- Home
- Publications
- Publication Search
- Publication Details
Title
Myxoid liposarcoma and the mammalian target of rapamycin pathway
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 25, Issue 4, Pages 379-383
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-05-14
DOI
10.1097/cco.0b013e32836227ac
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
- (2012) A. Naing et al. CLINICAL CANCER RESEARCH
- Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model
- (2012) Elizabeth G Demicco et al. MODERN PATHOLOGY
- DDIT3 Gene Break-apart as a Molecular Marker for Diagnosis of Myxoid Liposarcoma—Assay Validation and Clinical Experience
- (2011) Sonia Narendra et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
- (2011) Alberto S. Pappo et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor response to sunitinib malate observed in clear-cell sarcoma
- (2010) S. Stacchiotti et al. ANNALS OF ONCOLOGY
- Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma
- (2010) T. Negri et al. CLINICAL CANCER RESEARCH
- Trabectedin therapy for sarcomas
- (2010) Paolo G Casali et al. CURRENT OPINION IN ONCOLOGY
- Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib
- (2010) Silvia Stacchiotti et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
- (2010) Andrew J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
- (2010) Piotr Rutkowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of myxoid liposarcoma-associated FUS–DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay
- (2010) Martin P Powers et al. MODERN PATHOLOGY
- Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response
- (2010) S. Stacchiotti et al. MOLECULAR CANCER THERAPEUTICS
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
- (2010) Jordi Barretina et al. NATURE GENETICS
- mTOR signaling and drug development in cancer
- (2010) Janet Dancey Nature Reviews Clinical Oncology
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays
- (2009) Hongwei Cheng et al. HUMAN PATHOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
- (2009) David Olmos et al. LANCET ONCOLOGY
- Targeting Apoptosis Resistance in Rhabdomyosarcoma
- (2008) Simone Fulda CURRENT CANCER DRUG TARGETS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started